Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

pneumocystosis (PCP) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

pneumocystosis

MONDO:0019121

Also known as:PCPPJPPneumocystis

Find Clinical TrialsTrials

Overview

Human pneumocystosis is caused by an infectious agent, which (after recent nomenclature and taxonomy revisions) is now classed as the fungus Pneumocystis jiroveci. The prevalence is unknown. Pneumocystis jiroveci is an opportunistic infectious agent, developing in immunosuppressed patients. It is an air-borne infection, localized to the lungs. However, extrapulmonary involvement is seen in AIDS patients. The disease manifests progressively with coughing, respiratory problems (dyspnea) and fever, followed by acute respiratory insufficiency and death within a few weeks in untreated cases. The most reliable diagnostic method is bronchoalveolar lavage. The treatment of choice is cotrimoxazole.

Treatments3 FDA approved

Clinical Trials17 registered · 6 recruiting

Diagnosis

Biomarker and diagnostic research for pneumocystosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for pneumocystosis, including PENTAMIDINE ISETHIONATE (PENTAM 300, approved 1984) and ATOVAQUONE (MEPRON, approved 1995). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

17 clinical trials registered, 6 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 4 PHASE4, 3 PHASE3, 1 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06890078](https://clinicaltrials.gov/study/NCT06890078)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 12:11 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:723

GARD

Genetic and Rare Diseases Info Center

GARD:4386

Questions for Your Care Team

→What are the benefits and potential side effects of PENTAM 300 for managing pneumocystosis?
→Are any of the 17 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
Primaquine phosphate	Primaquine phosphate	Sanofi Winthrop, Inc.	1993	—	Designated
Clindamycin	Clindamycin	Pharmacia & Upjohn	1988	—	Designated

Research Type	Count	% of Total
Research summaries	54	34%
Disease patterns and progression	39	24%
Clinical study results	24	15%
Patient case studies	16	10%
Laboratory research	14	9%
Testing and diagnosis research	12	7%
New treatment approaches	2	1%

Kisho

pneumocystosis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

pneumocystosis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications